Skip to main content

Subcutaneous Securement System Best for Reaching End of PICC Need

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Aug. 31, 2023 -- A subcutaneous anchor securement system (SASS) is superior for assisting oncology patients to reach the end of need with a single peripherally inserted central catheter (PICC), according to a study published online Aug. 1 in The Journal of Vascular Access.

Michelle L. Hawes, R.N., from Data to Wisdom Research Consulting in Bloomington, Indiana, and colleagues conducted a retrospective study to examine oncology patients' ability to finish their therapy with one PICC using implant and explant data for adult oncology patients from 2007 to 2021. All patients received a PICC with an adhesive securement device (ASD) or SASS.

The researchers found that partial or complete dislodgement causing unplanned PICC removal occurred for 12 and 0.4 percent of those with ASD and SASS, respectively. The probability of reaching the end of need with one PICC at two years was 68 percent and more than 95 percent, respectively, regardless of the reason for premature removal, with a significant difference between the two securement devices (P < 0.0001).

"Based on the evidence, the best instrument for securing a catheter throughout a patient's therapeutic need is the subcutaneous anchoring securement device," Hawes said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

First Responders With More Debris Exposure Have Higher Risk of Early Dementia

FRIDAY, June 14, 2024 -- More severe exposure to dust or debris among World Trade Center (WTC) responders is significantly associated with a higher risk of dementia at <65...

1990 to 2019 Saw Increase in Life Expectancy in Seniors With T1DM

FRIDAY, June 14, 2024 -- From 1990 to 2019, there was an increase in life expectancy in older people with type 1 diabetes mellitus (T1DM), according to a study published online...

Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy

FRIDAY, June 14, 2024 -- Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.